Member Info for SamJSung

Following a formal search process, and having taken into account the feedback of a number of Quantum's major shareholders who are fully supportive of the strategy to simplify and focus the Group, the Board has today appointed Chris Rigg to the position of Chief Executive Officer ("CEO") on a permanent basis. Chris was appointed to the Board as Chief Financial Officer ("CFO") in March 2016 and has been Acting CEO since 1 August 2016. The Board has commenced a formal search process for a new CFO but, in the interim, as well as permanent CEO, Chris will remain as CFO until a replacement for that role is appointed. Quantum is also pleased to announce the appointments to the Board of Ian Johnson as non-executive Chairman; Christopher Mills as non-executive Director and Dr John Brown as Senior Independent non-executive Director. The Board has commenced a formal search process for a further non-executive Director. John Clarke and Sheila Kelly, non-executive Chairman and non-executive Director respectively, have resigned from their positions on the Board with immediate effect to focus on other Directorships and new business appointments.

Robins... I was NOT clever enough to get out before the major fall... it is now clear why the CEO and CFO left QP.. They should be banned from holding any form of office in any PLC... I presume the Chairman (John Clark) and Sheila Kelly will soon follow... Chris Rigg's credibility to continue in his joint role as CEO / CFO is very questionable... I still cannot belive that on the 31st Aug the following was announced by the Company.. 'The Board continues to expect the Group to meet market expectations for the full year to 31 January 2017' Then ... Boom , how the mighty fall ! and left many of us with substantial losses in value of our holdings.. So what next...A new CEO .. this really should have been announced with the half year results .. Poor judgement by QP not to have done so.. likewise with the new Non... Executives ... The Chairman really is Hopeless and have said this on so many occasions.. Closing down Nu Pharm Business is the right thing to do... BUT should never have been acquired to start with..60 jobs plus will go as a result.. The new CEO will likely use his appointment to prepare for a placing to possibly half current debt ... diluting existing shareholders by an estimate of 25%.. but necessary for both survival and growth.. A simplified business model is needed...focused on the core business.. and further closures I suspect can be expected.. There are some gems within QP... The company is POOR at Sales, Marketing and Communications...It need a model based on Partnerships and risk sharing as opposed to trying to do everything itself...and doing many things badly.... Professionals in Sales Marketing and .Communication need to be engaged and current owners of such titles in the main removed fortwith...They are simply not up to the job.. as has been demonstrated by current results.. Management numbers need to be vastly reduced.. the number of MD's Senior Management etc would suit a company like GSK but certainly NOT QP... In summary the Company was run lacking a real strategy, focus and handle on costs.. It lacked a board of Directors capable of holding the CEO to account ..and thre result was a sprawling mess of a business needing capital to stand still let alone grown.. The future is interesting ... I would know expect the Institutional Investors to be all over QP with their demands .. and this is supported by many increasing their holdings and others desperate to get back their original investment... Both the Ex CEO , CFO and Chairman should be thoroughly ashamed of themselves ... Future employers of these individuals watch out ! A new start with a new CEO / CFO and Chair can steer this company back from the brink to a real position of strength in its chosen markets... not forgetting a new generation of Partnerships and Products including Biodose / Biodose Connect.

TR-1 Notification of Major Interest in Shares This is the formal document informing Quantum that Royal London have sold shares which were above 3% to well below this figure. They have reduced their holding from .3,784,000 to 285,251 in other words they have virtually sold all of their holding in QP.

Robins.. I am with you.. I have pointed out before the deep weaknesses of the Board, The Chairman especially. Chris Rigg was also responsible for strategy before being appointed CFO.. and look how that has turned out...One can see why the ex CEO and CFO departed.. and their legacy. The Group needs a Pharma Expert on Board.. a tried and tested CEO, a New Chairman.. and critically a Director of Marketing and Sales.. I would also sack the Chief Legal officer and the Shareholder Communications team... The last update saying everything was OK and now this... just smacks of incompetence. and questionable legality...

Yes the trade took place at 8.20am 800K at 40p.... £320K bought in one trade..

We now know why the both the CEO and CFO left the Company.. But we have to move on..Get all the bad news out of the way and ... Go forward and upwards The Acting CEO has put in place a focused rationalisation and growth plan...This year might be classed as a re-building year... With a new strategy and a new CEO..the future is more stable for both growth, profitability and an improved share price.. I would still sack the Chairman... Hopeless and get a senior sales and marketing director on board.. they simply do not have the talent internally.especially for Biodose / Connect.

Robins: Some thoughts . I have only access to Trade information also... There are regular sales of blocks of 10K, 20K, 50K shares.. If they are not from Mr Scaife's holding ...and that was substantial , it may becoming from the previous CFO, or possibly those institutional holders who sit invisibly below the 3% mark... One such institution is Oryx International who held just over 3% sold 250K or so and went below 3% and hence we have no visibility of their current holding.. or what remains. This raises another interesting issue, QP has 2 Brokers ...it cannot be rocket science for either or both to know where the the large sales are coming from.. and importantly where they are going... If there is no change on the current institutional holdings ... then I suspect that QP themselves already know who it is that is selling...A look at the share register might even tell the answer. I still believe that Marketing and Sales are QP's weakness, Communications are appalling and even the recruitment of some Senior Comms Guru has not changed my opinion.. What therefore appears to be the real issue.? Leadership , Leadership and leadership...An invisible Chairman who has too many other Distractions and Duties with other Companies.. Leadership, A CFO acting as CEO .. a rather unbelievable situation .. yet its is really the case at QP. Leadership, Exploiting to the full its Intellectual Property..e.g Biodose, Biodose Connect etc... Very Poorly being executed... or communicated.. What is needed is Quality Management steering this unique company in the right direction.. Somebody who can talk the talk and importantly Deliver over and above shareholders expectations..

I suspect that Mr Scaife's holding is being sold in daily blocks of between 50K -100K shares. No RNS currently has been issued to show that any of the major holders have reduced their holding... The half year results are imminent.. and hopefully together with a positive update .. an announcement on the new CEO.. I am uncomfortable that one man doing both CEO and CFO functions can go on for much longer... Either they cannot find anybody or a possible major organisational restructuring may be on the cards hence the delay..

Further large blocks of QP shares continue to be sold... Hence the decline in the share Price.. Results for the six months ended 31 July 2016 are due on Tuesday, 4 October 2016....Is somebody in the know as to waht we can expect ? No RNS has been issued by any of the Institutional shareholders selling down their stake. My thoughts focus on Mr Scaife selling down his holding.. Interestingly enough, No appointment (yet) of a new CEO, No updated Comment on Futura Medical's recent announcement.. This company has so much going for it .. Yet it's communications to shareholders and I suspect the wider business community are APPALLING..

Is today's continuous sells of large blocks of QP shares the result of ex CEO selling down his considerable holding? Or the result of one of the Major holders of QP stock deciding that they have had enough... I would point out that a combined CEO and CFO is far from ideal for any company .. let alone one as complex as QP.. The Chairman should speed up considerably the new CEO appointment ... every day that passes seems to bring further share sales and a lower share price.... What ever happened to Succession Planning ! The Chairman has a lot to answer .. Once the appointment is complete he should offer his resignation and move on..

Last part of bulletin In fact Futura’s partner Quantum Pharma has already managed to have MED2002 categorised as an unlicensed special product that can be prescribed by doctors here in the UK. Not just that it is eligible for full NHS reimbursement. It is probably more appropriate to classify Futura as a med-tech rather than a traditional pharma or biotech firm. And this is a crucial distinction. For what it has created is a mode of action that gets drugs through the skin more quickly and effectively than other gels of this type. It is a patented delivery method. For erectile dysfunction, it is incorporated with glyceryl trinitrate, which has been used to treat angina for decades. You won’t be surprised to learn, then, the technology is being developed to carry traditional and well tolerated painkillers quickly and effectively to the point they are most needed. It means the company is not a one trick pony – it has a pipeline quick-to-market products that have consumer and medical indications.

HFWizard...The full article regarding Futura's successful clinical trial and the discovery of QP as its partner is below.. The temporary CEO should try to get QP's Communications Actioned...The Chairman is hopefully well on the way to making a necessary permanent appointment .. and returning the Temp CEO back to his day job of CFO where Marketing Communications are NOT part of his remit.. If this is not 'Great news' to be shouting about then what is... What a failure of Corporate communications by QP. Shares in Futura Medical PLC (LON:FUM) doubled in value after the company announced a pivotal clinical trial of its gel for erectile dysfunction (ED) had been a resounding success. It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations. City broker N+1 Singer said it thought the firm’s treatment, MED2002, had “significant potential” following the publication of a study that “successfully demonstrated” efficacy, safety and speed of onset. MED2002 scored success across all groups tested – mild, moderate and severe cases – but did particularly well in men with mild ED. Some 82% with the mild form of the condition said the gel began working within 10 minutes, with 54% reporting onset within five minutes. No safety concerns were registered, which means the gel could be positioned as a consumer health product at the right dosage as well as being a prescription-based medicine. Futura said the results will form the basis of “commercialisation strategy” for MED2002. “The headline data from the study indicate that we have a breakthrough ED product that is not only effective but may also combine potentially the world's fastest speed of onset for an ED treatment with a very favourable safety profile,” said chief executive James Barder. “We will carry out further analysis of the results in the next few days and are very excited by the commercial potential of this product." By 11.30am, the shares were up 31p, or 108%, to 59.5p, valuing the business at £43mln. “We believe the market potential is significant, and will update our forecasts as soon as the commercialisation strategy for the product has been clarified,” said the City broker N+1 Singer in a note. Research commissioned by Futura found a widespread dissatisfaction with the current crop of ED pills, with the speed of onset being the most common complaint. MED2002 provides a far more rapid solution to what's out there currently. It takes five to ten minutes before the effect is felt versus 20 for the likes of Viagra. All of this provides an opportunity: a ready-made market of men who either can’t or don’t like taking the current help available. In fact Futura’s partner Quantum Pharma has already managed to have MED2002 categorised a

Futura Medical made a great announcement today about regarding pivotal clinical trial of its gel for erectile dysfunction (ED) had been a resounding success. Its partner is Quantum Pharma.. QP recently appointed a new Corporate Communications Manager... Where is QP's Corporate Communication on their Partners success and importantly what it means to QP's prospects.. I continually remark on QP's Marketing / Communication failures but surely in this case they could have got their act together and issued simultaneously a positive Bulletin.. even an RNS to less then tolerant shareholders.. Perhaps the new CEO needs to kick hard its Sales and Marketing people whre it hurts .. and quickly.. Futura's share Price rose tremendously this morning on their announcement ... Why are QP waiting to comment.?

Futura shares double after successful clinical trial Share 14:24 07 Sep 2016 It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations. Futura’s partner Quantum Pharma has already managed to have MED2002 categorised as an unlicensed special product that can be prescribed by doctors here in the UK. Not just that it is eligible for full NHS reimbursement.

There continues to be substantial selling in blocks of 5000/10000.. This might be a managed sell of ex CEO Mr Scaife's holding. its a shame that QP did not attempt to acquire all of Scaife's holding and use as Treasury shares.. but supposedly they know best... As previously commented, The Company has been guilty of over promising and under delivering in recent times and a more conservative statement on performance is welcomed.. hopefully demonstrating Over and above expectations.. With half year results expected on the 4th October ... This should be an opportunity to both update the market on overall progress including Biodose / Biodose Connect and the appointment of the new CEO.. I still believe that a new Chairman for QP is required.. It amazes me that he had not planned any for of succession planning for Andrew Scaife.. and we have the unusual situation of the CFO acting CEO... Can both jobs really be done by one person ? The Chairman needs to move fast with a permanent appointment and start driving the share price and company performance substantially forward.

Oryx International Growth Fund..today notified QP that it had reduced its share holding from 3,789,429 shares to 3,500,000 . Yet it was just recently on the 27th July 2016 Oryx notified that it had increased its holding from 3,500,000 to 3,789,429 3,789,429 representing 3.03% of QP's share Capital.. What has happened in the last 4 weeks for it to return to its original stake.? A rising share price? or have Oryx off loaded to a potential bidder ... perhaps we might expect another RNS pretty soon giving us a clue ?

QP's share price has a lot of ground to make up... But is making great progress due to the following:- (1) Appointment of new CFO Chris Rigg currently acting CEO (2) Appointment of a new CEO (details awaited) (3) Removal of Andrew Scaife (4) A validated pipeline of new products being approved and launched substantially more effectively than previous. (5) Uniqueness of Bio Dose / Bio Dose connect. (6) On track to meet target earnings and EBITDA for 16/17 (7) The appointment of Lisa Brigham as its corporate communications manager,This is real evidence that QP is serious about improving its Marketing and Wider Communications ability to improve both Sales, Margin and importantly Communications with shareholders / stakeholders... Including Institutional shareholders.. (8) The addition of the Slater Investments to the Major Shareholder List. There appears also to be a number of large trades going through the market over the past week... It might be Mr Scaife reducing his not insubstantial holding... But it appears at least to me either other Major shareholders are topping up ( an RNS will confirm this in the near future) or a predator is stake building.. There are a limited number of free Float shares and if institutions are topping up then we can expect further rises in the value of QP shares in the run up to interim results.. The appointment of the new CEO should add further impetus to the share price... Product launches should remain a secret until final approval and launch plans confirmed in order to stop competitors either copying or attempting to derail QP's launch plans ... Hence no sight of them on the Company website.. QP has previously quoted a total Pipeline of X products (audited externally) and an estimated overall value to the company... No doubt that this is being added to continuously. This is a unique company and with the changes detailed above and a set of unique products and services .. We have a real opportunity to retrace previous high's in its share price,

What will Mr Scaife do with his QP holding (approx 3.2% of the Company)...Will it be sold to a predator as a base to make a full bid? Is it likely to be acquired by one or more institutions to top up their holding, or will it just overhang the market with gradual selling by Mr Scaife over a period of time? The market has responded positively to Scaife's departure... It still seems a little odd to me that he did not hang around until a permanent CEO was appointed.. but his resignation really left him in no mans land with little or no authority to continue to Manage, Lead and Inspire the Company .. so better he went earlier rather than later.. I still believe that Nicola Massey one of QP's MD's should be a serious contender for the CEO role.. My preference is for a Pharma Person as opposed to a numbers / finance person ( we have that in the CEO).. The next few weeks will be interesting... and possibly very rewarding for shareholders.

As at 13 May 2016, the Company has been notified of the following interests in 3% or more of the issued ordinary share capital of the Company: Oryx International Growth Fund Limited 3,789,429 3.03 Yet Oryx additional holding was only achieved on the 27th July 2016 as notified to shareholders yesterday.. The Registers update (failure) again reflects QP's inability to manage its internal processes correctly.. Hopefully shareholders will have sight of what the REAL QP major shareholdings are sooner rather than later..

Agree with your perspective...The uniqueness' of this range of products...should generate substantial sales..there appears to be a ready market and substantial unmet needs.. What puzzles me is why with the uniqueness of the QP portfolio the BOD have not established a core of international partners to exploit every single product to the full...This more so applies to Biodose..QP should be seeking global licences immediately.. One of my major concerns with QP is the flaws in the Senior Management Team...there are well paid MD,s across the QP divisions...but very poor talent when it comes to Marketing and Sales... The new MD should ensure that QP focus on Marketing and Sales across the Divisions and integrate this activity with every product launch... QP has a penchant for launching products without I believe thinking through how to leverage each product for both revenue and profit to the full.. It is no good having the worlds best portfolio if it is poorly marketed and its revenues are not optimised...and in a global economy that means thinking Globally... I still believe that both a new CEO and a new Chairman plus a severe rationalisation of Senior Management with a new emphasis on Marketing and Sales and importantly International Partnerships.